Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2023-08-17 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
海通证券股份有限公司关于上海宣泰医药科技股份有限公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Haitong Securities regarding the unlocking and listing of restricted shares of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It includes specifics about the types and quantities of restricted shares becoming tradable, shareholder commitments, and compliance with relevant laws and regulations. The document does not contain financial statements or performance data but focuses on the regulatory and compliance aspects of share unlocking and circulation. This fits the category of a Regulatory Filing (RNS) as it is a compliance and disclosure announcement related to share circulation, not a financial report or a voting result announcement. The document length is under 5,000 characters, and it is not a report publication announcement but a regulatory disclosure.
2023-08-17 Chinese
关于公司产品枸橼酸托法替布缓释片获得美国FDA批准文号的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the FDA approval of their drug product ANDA (Abbreviated New Drug Application) for a generic drug. It includes details about the drug, patent status, and potential impact on the company. The document is short (1224 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed regulatory filings like 10-K or IR. It is not a report publication announcement since it is the announcement itself. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about FDA approval and patent litigation status, which does not fit other more specific categories.
2023-08-09 Chinese
关于签订产品许可协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. about signing a product licensing agreement with LANNETT COMPANY, INC. It details the terms of the agreement, including intellectual property licensing, product development responsibilities, milestone payments, profit sharing, and the impact and risks of the transaction. The document is a formal disclosure of a business transaction rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data, nor is it a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it relates to a significant business agreement affecting the company's capital and revenue prospects through licensing and milestone payments.
2023-08-06 Chinese
关于独立董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of an independent director from the company's board. It discusses the director's departure, legal compliance, and the process for appointing a new independent director. There is no financial data, no report attached or referenced as being published, and no mention of earnings, audits, or other report types. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-07-24 Chinese
2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the implementation of the 2022 annual equity distribution (dividend payment). It details the dividend per share, relevant dates (record date, ex-dividend date, payment date), tax treatment, and shareholder eligibility. The document is short (2490 characters) and focuses on dividend distribution specifics rather than presenting financial statements or comprehensive financial performance. It is not a full annual report or earnings release but a formal announcement of dividend amount and payment details. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2023-06-29 Chinese
关于公司产品西格列汀二甲双胍缓释片获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the approval of a drug registration certificate for a product called 'Sitagliptin Metformin Sustained Release Tablets'. It includes details about the drug, its registration, market impact, and risk warnings. The document is short (955 characters) and is an announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management changes. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category about product approval and company impact. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-06-13 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.